Brolucizumab · intravitreal injection
Injections & Implants
Approved uses
Neovascular (wet) age-related macular degeneration
6 mg (0.05 mL of 120 mg/mL) intravitreally monthly for 3 doses, then every 8 to 12 weeks
Carries a labeled risk of retinal vasculitis and vascular occlusion the other anti-VEGF agents do not
Diabetic macular edema
6 mg (0.05 mL of 120 mg/mL) intravitreally every 6 weeks for 5 doses, then every 8 to 12 weeks
Contraindications
- Ocular or periocular infection
- Active intraocular inflammation
- Known hypersensitivity to brolucizumab or any of the excipients in BEOVU
Intravitreal injection, 6 mg (0.05 mL of 120 mg/mL) in a single-dose pre-filled syringe or single-dose vial.
Brolucizumab is a human VEGF inhibitor. Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF 110, VEGF 121, and VEGF 165 ), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability.
Warnings & Precautions
- Endophthalmitis and Retinal Detachment: Intravitreal injections, including those with BEOVU, have been associated with endophthalmitis and retinal detachment. Proper aseptic injection techniques must always be used when administering BEOVU. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
- Retinal Vasculitis and/or Retinal Vascular Occlusion: Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of BEOVU. These immune-mediated adverse events may occur following the first intravitreal injection. Discontinue treatment with BEOVU in patients who develop these events. Patients who experience intraocular inflammation should be closely monitored. Instruct patients to report any change in vision without delay.
- Increase in Intraocular Pressure: Acute increases in intraocular pressure (IOP) have been seen within 30 minutes of intravitreal injection, including with BEOVU. Sustained IOP increases have also been reported. Both IOP and perfusion of the optic nerve head must be monitored and managed appropriately.
- Thromboembolic Events: Although there was a low rate of arterial thromboembolic events (ATEs) observed in the BEOVU clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. Arterial thromboembolic events are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). In HAWK and HARRIER, the ATE rate during the first 96 weeks was 4.5% in the pooled brolucizumab arms and 4.7% in the pooled aflibercept arms.
Common Side Effects
The most common adverse reactions reported in patients receiving BEOVU are vision blurred, cataract, conjunctival hemorrhage, eye pain, and vitreous floaters.
Pregnancy: There are no adequate and well-controlled studies of BEOVU administration in pregnant women. In pregnant monkeys, intravitreal brolucizumab did not indicate any harmful effects with respect to pre- or postnatal development at 10-fold the maximum recommended human dose (MRHD) on a mg/kg basis. Based on the anti-VEGF mechanism of action, treatment with BEOVU may pose a risk to human embryo-fetal development. BEOVU should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
Lactation: There is no information regarding the presence of brolucizumab in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production/excretion. Breastfeeding is not recommended during treatment and for at least one month after the last dose when stopping treatment with BEOVU.
The safety and efficacy of BEOVU in pediatric patients has not been established.